1856-P: Expanding the Use of Automated Insulin Delivery in Puerto Rico, from Type 1 to Type 2 Diabetes

Introduction and Objective: Diabetes is a major public health challenge in Puerto Rico. High adult prevalence (18.0%)1 and cross-sectional studies showing >65% of Puerto Ricans with T2D fail to achieve the A1c<7.0% target2 contribute to high rates of diabetes-related complications. This analysis reports real-world MiniMed™ 780G (MM780G) glycemic outcomes among individuals with diabetes in Puerto Rico. Methods: Carelink™ data (Jan 2023 to Oct 2025) of consenting MM780G users from Puerto Rico aged ≥18 years with self-reported T1D and T2D were analyzed. Glycemic outcomes were explored in the overall group and in those with recommended optimal settings (ROS: glucose target 100 mg/dL and active insulin time 2h, for ≥95% of the time). Results: Data from 1,506 T1D (41.8 ± 14.8 years) and 367 T2D (61.1 ± 11.0 years) users were analyzed. Overall, both groups achieved all consensus-recommended goals (Figure 1). ROS were used by 59.4% of T1D users and 58.3% of T2D users, and were associated with higher TIR and TITR, increasing both variables ~7% in T1D and ~10% in T2D, compared to non-ROS users (Figure 1). Conclusion: The MM780G system allowed insulin-treated T2D users in Puerto Rico to achieve ADA-recommended glycemic targets, mirroring the outcomes seen in T1D. Adoption of ROS translated into larger real-world glycemic benefits, highlighting the amplified impact of optimizing AID in diabetes management. Disclosure M. Castro: Employee; Current; Medtronic. M. Liu: Employee; Current; Medtronic. J. McVean: Employee; Current; Medtronic.